Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases

Clinical trial NCT07614477 · RECRUITING

Trial details

NCT number: NCT07614477
Sponsor: Everest Medicines (China) Co.,Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Minimal Change Disease (MCD)IgA Nephropathy (IgAN)Focal Segmental Glomerulosclerosis (FSGS)

Start date: 2026-05-20
Primary completion: 2028-12-31
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.